Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin and Positive Valence System in Treatment-Resistant Depression
2022-501092-11-00Phase 2Completed
- Sponsor
- CHU Nîmes
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in treatment-resistant depression (TRD), sponsored by CHU Nîmes. Primary endpoint: Change in brain activity in regions involved in effort assessment. Started Sep 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2022-501092-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501092-11-00.